Gaurav Syal, Edward Barnes, Laura Raffals, Elie Al Kazzi, John Haydek, Manasi Agarwal, Siddharth Singh
{"title":"Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-A Systematic Review and Meta-Analysis.","authors":"Gaurav Syal, Edward Barnes, Laura Raffals, Elie Al Kazzi, John Haydek, Manasi Agarwal, Siddharth Singh","doi":"10.14309/ajg.0000000000003136","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pouchitis and Crohn's-like disease of the pouch (CLDP) are common in patients who undergo ileal pouch anal anastomosis for ulcerative colitis. We conducted separate systematic reviews to evaluate the effectiveness of available interventions to prevent and treat pouchitis and CLDP.</p><p><strong>Methods: </strong>Through systematic literature reviews, we identified studies that evaluated the effectiveness of probiotics, antibiotics, 5-aminosalicylates, nonsystemic oral corticosteroids, and advanced therapies for prevention and treatment of pouchitis and CLDP for meta-analysis. Primary outcomes were occurrence of pouchitis for pouchitis prevention and clinical response for pouchitis and CLDP treatment. We estimated the relative effectiveness of these interventions using the existing placebo response rates or hypothetical spontaneous improvement rates derived from clinical trials of pouchitis, ulcerative colitis, and Crohn's disease.</p><p><strong>Results: </strong>Probiotics were effective for primary (relative risk [RR] 0.18; 95% confidence interval [CI] 0.05-0.62) and secondary prevention (RR 0.17; 95% CI 0.09-0.34) of pouchitis. Antibiotics were effective for treatment of acute and chronic pouchitis (12 cohorts; RR 1.67; 95% CI 1.34-2.01; response rate 65%; 95% CI 52-75) with ciprofloxacin and metronidazole-based regimens being more effective than rifaximin. Advanced therapies were effective for treatment of chronic antibiotic-refractory pouchitis (31 cohorts; RR 1.71; 95% CI 1.28-2.56; response rate 50%; 95% CI 43-57) and CLDP (10 cohorts; RR 2.49; 95% CI 1.87-3.73; response rate 74%; 95% CI 68-79) without significant difference between classes.</p><p><strong>Discussion: </strong>Multiple medical interventions are effective for prevention and treatment of pouchitis and CLDP. Given the overall low quality of data, further research is needed to confirm these findings.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.0000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ajg.0000000000003136","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Pouchitis and Crohn's-like disease of the pouch (CLDP) are common in patients who undergo ileal pouch anal anastomosis for ulcerative colitis. We conducted separate systematic reviews to evaluate the effectiveness of available interventions to prevent and treat pouchitis and CLDP.
Methods: Through systematic literature reviews, we identified studies that evaluated the effectiveness of probiotics, antibiotics, 5-aminosalicylates, nonsystemic oral corticosteroids, and advanced therapies for prevention and treatment of pouchitis and CLDP for meta-analysis. Primary outcomes were occurrence of pouchitis for pouchitis prevention and clinical response for pouchitis and CLDP treatment. We estimated the relative effectiveness of these interventions using the existing placebo response rates or hypothetical spontaneous improvement rates derived from clinical trials of pouchitis, ulcerative colitis, and Crohn's disease.
Results: Probiotics were effective for primary (relative risk [RR] 0.18; 95% confidence interval [CI] 0.05-0.62) and secondary prevention (RR 0.17; 95% CI 0.09-0.34) of pouchitis. Antibiotics were effective for treatment of acute and chronic pouchitis (12 cohorts; RR 1.67; 95% CI 1.34-2.01; response rate 65%; 95% CI 52-75) with ciprofloxacin and metronidazole-based regimens being more effective than rifaximin. Advanced therapies were effective for treatment of chronic antibiotic-refractory pouchitis (31 cohorts; RR 1.71; 95% CI 1.28-2.56; response rate 50%; 95% CI 43-57) and CLDP (10 cohorts; RR 2.49; 95% CI 1.87-3.73; response rate 74%; 95% CI 68-79) without significant difference between classes.
Discussion: Multiple medical interventions are effective for prevention and treatment of pouchitis and CLDP. Given the overall low quality of data, further research is needed to confirm these findings.
简介:在因溃疡性结肠炎(UC)而接受回肠袋肛门吻合术的患者中,常见的病症是肠袋炎和肠袋克罗恩病(CLDP)。我们分别进行了系统性综述,以评估现有干预措施对预防和治疗溃疡性结肠炎和溃疡性肠病的有效性:通过系统性文献综述,我们确定了评估益生菌、抗生素、5-氨基水杨酸盐、非系统性口服皮质类固醇和先进疗法对预防和治疗小袋炎和 CLDP 的有效性的研究,并进行了荟萃分析。主要研究结果是:预防胃袋炎的研究结果是胃袋炎的发生率,治疗胃袋炎和 CDLP 的研究结果是临床反应。我们使用现有的安慰剂反应率或从治疗小袋炎、UC 和克罗恩病的临床试验中得出的假定自发改善率来估算这些干预措施的相对有效性:益生菌对小袋炎的一级预防(RR 0.18;95% CI 0.05-0.62)和二级预防(RR 0.17;95% CI 0.09-0.34)有效。抗生素对治疗急性和慢性胃袋炎有效(12 个队列;RR 1.67;95% CI 1.34-2.01;应答率 65%;95% CI 52-75),其中环丙沙星和甲硝唑方案比利福昔明更有效。先进疗法对治疗慢性抗生素难治性胃袋炎(31 个队列;RR 1.71;95% CI 1.28-2.56;应答率 50%;95% CI 43-57)和 CLDP(10 个队列;RR 2.49;95% CI 1.87-3.73;应答率 74%;95% CI 68-79)有效,但不同类别之间无显著差异:结论:多种医疗干预措施对预防和治疗胃袋炎和 CLDP 均有效。鉴于数据质量总体较低,需要进一步研究来证实这些发现。
期刊介绍:
Published on behalf of the American College of Gastroenterology (ACG), The American Journal of Gastroenterology (AJG) stands as the foremost clinical journal in the fields of gastroenterology and hepatology. AJG offers practical and professional support to clinicians addressing the most prevalent gastroenterological disorders in patients.